Hoth Therapeutics achieves 100% clinical response and 50% reduction in disease severity in EGFR-treated cancer patients.

By Week 6, the primary endpoint ARIGA showed an impressive approximately 50% enhancement from the baseline, leading all evaluated patients to achieve low-severity disease levels. Furthermore, secondary endpoints indicated around a 34% amelioration in oncology toxicity according to the CTCAE classification and a notable 37% decrease in patient-reported pruritus. This promising data was revealed in New York on January 22, 2026.